Detalhe da pesquisa
1.
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
Lancet Oncol
; 24(5): 443-456, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37142371
2.
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Lancet
; 399(10323): 447-460, 2022 01 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34953525
3.
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
Int J Cancer
; 151(3): 422-434, 2022 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35411939
4.
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial.
PLoS Med
; 19(6): e1003998, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35671327
5.
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
N Engl J Med
; 377(4): 338-351, 2017 07 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-28578639
6.
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Lancet
; 392(10162): 2353-2366, 2018 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30355464
7.
New developments in metastatic prostate cancer therapy.
Practitioner
; 259(1781): 21-4, 2-3, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26529826
8.
Will chemotherapy change the management of prostate cancer?
BJU Int
; 118(2): 190-2, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-26696125
9.
Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial.
JCO Precis Oncol
; 4: 882-897, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35050761
10.
This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols.
Trials
; 20(1): 264, 2019 May 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-31138317
11.
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer.
Eur Urol
; 76(6): 719-728, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31447077
12.
Uptake and radiological findings of screening cerebral magnetic resonance scans in patients with hereditary haemorrhagic telangiectasia.
Intractable Rare Dis Res
; 7(4): 236-244, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-30560015
13.
Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial.
J Clin Oncol
; 35(14): 1530-1541, 2017 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28300506
14.
Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform.
Eur Urol
; 70(6): 906-908, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27450106
15.
Can Iron Treatments Aggravate Epistaxis in Some Patients With Hereditary Hemorrhagic Telangiectasia?
Laryngoscope
; 126(11): 2468-2474, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27107394
16.
Autosomal dominant acute necrotising encephalopathy: a case report with possible disease-expression modification by coincidental homocysteinuria.
Eur J Paediatr Neurol
; 15(2): 174-6, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-20570537
17.
PARP inhibitors and stratified treatment of prostate cancer.
Expert Rev Anticancer Ther
; 16(12): 1213-1215, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27686597